Highest-materiality recent filing
Axogen Q1 revenue $61.5M (+27% YoY); raises FY 2026 revenue guidance to at least $270M
Q1 revenue $61.5M, up 26.6% YoY; gross margin expanded to 75.2% from 71.9%.
Axogen Q4 revenue $59.9M (+21%); FY2025 $225.2M; guides 2026 growth >=18%
Q4 revenue $59.9M (+21.3% YoY); net loss $13.2M ($0.28/sh); adjusted net income $3.5M ($0.07/sh).
Axogen prices $124M public offering at $31/share; proceeds to pay off $69.7M credit facility
Pricing of upsized 4M share offering at $31.00/share for gross proceeds of ~$124M (assuming no over-allotment).
Q4 2025 revenue ~$59.9M (+21.3% YoY); full-year 2025 revenue ~$225.2M (+20.2% YoY).
Axogen receives FDA approval of BLA for Avance nerve allograft under Accelerated Approval pathway
FDA approved Biologics License Application for Avance (acellular nerve allograft) for sensory, mixed, motor nerve discontinuities in adults and pediatric patients 1 month+.
Axogen Q3 revenue $60.1M (+23.5% YoY); raises FY revenue guidance to at least $222.8M
Net income of $0.7M ($0.01 EPS) vs net loss of $1.9M in Q3 2024; adjusted EPS $0.12 vs $0.07.
FDA extends PDUFA date for Axogen's Avance Nerve Graft BLA to Dec 5, 2025
FDA deemed Axogen's August 22 submission a Major Amendment, extending PDUFA goal date by three months to Dec 5, 2025.
Axogen Q2 2025 revenue $56.7M (+18.3% YoY); raises FY guidance to $219M
Q2 revenue $56.7M (+18.3% YoY); net income $0.6M ($0.01 EPS) vs loss of $1.9M ($0.04) year ago.
Axogen Q1 revenue $48.6M (+17.4% YoY); appoints Lindsey Hartley as CFO
Q1 revenue $48.6M, up 17.4% YoY; net loss $3.8M ($0.08/share) vs $6.6M loss in Q1 2024.
Axogen Q4 2024 revenue up 15.1% to $49.4M; reports first quarterly net income of $0.4M
Q4 revenue $49.4M (+15.1% YoY); gross margin 76.1% vs 74.6%.
Axogen reports Q4 2024 revenue $49.4M (+15.1% YoY); FY 2024 revenue $187.3M (+17.8%)
Q4 2024 revenue expected $49.4M, up 15.1% YoY; full-year 2024 revenue $187.3M, up 17.8%.
Axogen Q3 revenue $48.6M (+18% YoY), adjusted net income $3.1M; BLA accepted by FDA
Revenue $48.6M (+17.9% YoY); gross margin 74.9% vs 76.8% in prior year.
Axogen completes BLA submission to FDA for Avance Nerve Graft; priority review requested
FDA submission for Avance Nerve Graft completed under rolling review process on Sept. 6, 2024.
Axogen appoints Michael Dale as CEO; Karen Zaderej steps down, remains advisory
Michael Dale becomes CEO, President, and Director effective August 9, 2024; Karen Zaderej exits CEO role.
Axogen Q2 revenue up 25.6% to $47.9M; net loss narrows; raises FY guidance
Revenue $47.9M (+25.6% YoY); net loss $1.9M ($0.04/share) vs $6.7M loss prior year.
Axogen Q1 2024 revenue $41.4M (+12.9% YoY); net loss narrows to $6.6M; adj EBITDA turns positive
Revenue $41.4M, up 12.9% YoY; gross margin improved to 78.8% from 77.7%.
On May 8, 2025, Axogen, Inc. (the “Company”) announced the appointment of Lindsey Hartley as its Chief Financial Officer, effective May 12, 2025
Nir Naor, the Chief Financial Officer (the “CFO”) of the Company, will step down from his role effective May 11, 2025
On August 8, 2024, Axogen, Inc. (the “Company”), announced the appointment of Michael Dale as its Chief Executive Officer (“CEO”) and President, effective August 9, 2024 (the “Effective Date”).
Mr. Gregory Freitag was not re-nominated for re-election.
Max materiality 0.85 · Median 0.75 · Most common event earnings